ClinicalTrials.gg
RecruitingNCT06686381Updated Oct 29, 2026

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

A Phase 2 interventional study of Maximum TURBT and Chemotherapy + Immunotherapy Induction in Muscle-invasive Bladder Cancer, sponsored by American University of Beirut Medical Center. Recruiting at 1 site in Lebanon. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by American University of Beirut Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 29, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in the treatment of muscle-invasive bladder cancer.

Read the detailed description

Muscle-invasive bladder cancer (MIBC) is an aggressive form of bladder cancer, with a 5-year survival rate of about 40%.

The standard treatment for MIBC is induction platinum-based chemotherapy followed by radical cystectomy. Recently bladder preservation strategies have emerged as an alternative to radical cystectomy, particularly useful for patients who are unfit for surgery or would rather opt for non-surgical approaches. Knowing the high risks related to surgery and its significant complications, the investigators propose to implement 2 tetra-modalities treatment strategies to increase the chance of preserving the bladder and decrease the need of salvage cystectomy.

The purpose of this study is to assess the efficacy and safety of 2 bladder-preservation treatments plans called tetra-modalities:

First plan:

  • maximium TURBT
  • chemo-immunotherapy as induction phase (Avelumab added to chemotherapy)
  • radiation therapy
  • maintenance phase with Avelumab

Second plan:

  • Maximum TURBT
  • chemo-immunotherapy as induction phase (Avelumab added to chemotherapy)
  • radiation therapy
  • Watch and wait

Both tetra-modalities duration will last maximum of 2 years from patient inclusion.

These treatment plans are based on the synergistic action between immunotherapy, chemotherapy, and radiotherapy. The use of Avelumab in the maintenance group is supported by its proven success in treating advanced cancer and various studies looking at immunotherapy as a way to avoid or delay bladder removal.

02

Conditions studied

  • Muscle-invasive Bladder Cancer

Keywords

  • Muscle-invasive bladder cancer
  • Bladder preservation
  • Avelumab
  • Tetramodalities
03

In context

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.

Browse Urinary Bladder Neoplasms studies →

Lead sponsor

American University of Beirut Medical Center is the lead sponsor of 158 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form (ICF) before any trial related procedures.
  2. Male or female participant with ≥ 18 years of age at time of consenting.
  3. Participant is able and willing to comply with the requirements of trial protocol.
  4. Pathologically (histologically or cytologically) and radiologically confirmed newly diagnosed MIBC (T2-T4 N0 M0) or recurrent previously NMIBC.
  5. confirmed transitional cell carcinoma.
  6. Participant with Performance Status (PS) ≤ 1 at screening visit.
  7. An estimated of more than 6 months.
  8. At screening visit, LVEF >50% by echocardiography, for participants planned to receive DDMVAC.
  9. Participant must have adequate laboratory values at screening visit as follow:

    1. Hematologic:

      • (ANC) ≥ 1.5 × 10\^9/L
      • count ≥ 100 × 10\^9/L
      • ≥ 9 g/dL (may have been transfused)
    2. Hepatic:

      • Total level ≤ 1.5 ×
      • ≤ 2.5 × ULN
      • ALT ≤ 2.5 × ULN
    3. Renal:

      • Estimated > 50 mL/min according to the Cockcroft-Gault formula
      • Serum urea ≤ 1.5 x ULN
      • Serum creatinine ≤ 1.5 x ULN.
  10. Female participant of must have a negative serum pregnancy test at screening.
  11. For female participant of childbearing potential: use one of the following highly effective methods throughout the trial and for 30 days after the last Avelumab treatment administration.

    • combined (estrogen and progesterone) hormonal contraception associated with inhibition of ovulation: either oral, intravaginal or transdermal
    • progesterone-only hormonal contraception associated with inhibition of ovulation: either oral, injectable or implantable
    • intrauterine device (IUD)
    • intrauterine hormone-releasing system (IUS)
    • bilateral tubal occlusion
    • vasectomised partner (provided that partner is the sole sexual partner of the female trial participant and that the vasectomised partner has received medical assessment of the surgical success)
    • sexual abstinence

Exclusion criteria

Exclusion Criteria:

  1. Participant with non-muscle invasive bladder cancer or disease (M1) and/or lymph node positive.
  2. Participant who underwent radical cystectomy or is planned for radical cystectomy.
  3. confirmed squamous cell carcinoma, micropapillary carcinoma, neuroendocrine carcinoma, adenocarcinoma, or mixed histology.
  4. Participant had received treatment for urothelial carcinoma, with any of the following anti-cancer therapies prior the first dose of trial treatment: systemic chemotherapy, targeted small molecule therapy, or radiation therapy.
  5. Participant had received prior treatment with any drug or antibody (, anti-PD- L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody) targeting T-cell co-stimulation or checkpoint pathways.
  6. Participant who are not eligible to receive DDMVAC or Cisplatin-Gemzar.
  7. History of severe to Avelumab or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI- v5.0 Grade ≥ 3).
  8. Participant with hydronephrosis.
  9. Active infection requiring systemic therapy within 28 days before the first dose of trial treatment (e.g., urinary tract infection).
  10. History of testing positive for the (HIV) or known acquired immunodeficiency syndrome.
  11. virus (HBV) or virus (HCV) infection at screening visit (positive Hepatitis B surface antigen (HBsAg) or HCV RNA if anti-HCV antibody screening test is positive).
  12. Participant currently using medication, except for the following:

    • Intranasal, inhaled, topical , or local steroid injection (e.g., intra-articular injection).
    • Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  13. Active diseases that might deteriorate upon receiving an immune- stimulatory agent. Conditions such as vitiligo, psoriasis, diabetes type I, or hypo - or hyper-thyroid diseases not requiring immunosuppressive treatment are eligible.
  14. Participant has any of the following medical conditions: Addison's disease, thyroiditis/Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome, and Grave's disease.
  15. Any psychiatric condition that would prohibit the understanding or rendering of form.
  16. Hepatic insufficiency manifesting as clinical jaundice, hepatic encephalopathy, and/or variceal bleed within 60 days prior to screening.
  17. , active cardiovascular disease, such as:

    • Transmural myocardial infarction within 6 months of enrollment
    • Unstable angina
    • Congestive heart failure ( Classification Grade II or greater)
    • Serious cardiac arrhythmia requiring medical treatment
  18. Cerebral vascular accident/ stroke within 6 months of enrollment.
  19. End-stage renal disease requiring dialysis.
  20. Participant has severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior.
  21. Prior organ transplantation including allogenic stem-cell transplantation.
  22. Treatment with an agent within 28 days before the first dose of trial treatment.
  23. Participation in another clinical trial.
  24. Participants who are taking prohibited medication.
  25. Pregnant or breastfeeding women or who are planned to get pregnant or breastfeed during the trial.
  26. Vaccination within 4 weeks of the first dose of Avelumab is prohibited except for administration of inactivated vaccines.
  27. Persisting toxicity related to prior therapy with Grade > 1 (NCI-CTCAE v 5.0); with the exception of: alopecia, sensory neuropathy Grade ≤ 2, or other toxicity with Grade ≤ 2 not constituting a safety risk based on investigator's judgment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Arm A (Maintenance Avelumab)

    Arm A: TURBT followed by induction Chemo/immunotherapy (DDMVAC (6 cycles) + Avelumab (6 cycles) or cisplatin/Gemzar (4 cycles) + Avelumab (6 cycles). A clinical evaluation is scheduled at 4 months post-day1 cycle 1 with CT scan/MRI for chest/abdomen/pelvis (CTCAP), Cystoscopy with Biopsy and urine cytology. Then complete or near complete responders will undergo 20 fractions of hypo-fractionated radiotherapy 55 grays followed by Avelumab every 2 weeks for 12-month maintenance phase.

    Procedure: Maximum TURBT · Drug: Chemotherapy + Immunotherapy Induction · Radiation: Radiotherapy · Drug: Immunotherapy Maintenance

  • Experimental
    Arm B (W&W)

    Arm B: TURBT followed by induction Chemo/immunotherapy (DDMVAC (6 cycles) + Avelumab (6 cycles) or cisplatin/Gemzar (4 cycles) + Avelumab (6 cycles). A clinical evaluation is scheduled at 4 months post-day1 cycle 1 with CT scan/MRI for chest/abdomen/pelvis (CTCAP), Cystoscopy with Biopsy and urine cytology. Then complete or near complete responders will undergo 20 fractions of hypo-fractionated radiotherapy 55 grays followed by 1 year watch and wait.

    Procedure: Maximum TURBT · Drug: Chemotherapy + Immunotherapy Induction · Radiation: Radiotherapy · Other: Watchful waiting with supportive care

Interventions

  • ProcedureMaximum TURBT

    Total removal of the bladder tumor through TURBT

  • DrugChemotherapy + Immunotherapy Induction

    Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)

  • RadiationRadiotherapy

    Hypofractionated radiotherapy: 20 fractions, 55 Grays

  • DrugImmunotherapy Maintenance

    Maintenance Avelumab every 2 weeks for 12 months

  • OtherWatchful waiting with supportive care

    1 year watch and wait

06

What researchers measure

Primary outcomes

  1. to assess the proportion of patients who are radical cystectomy free at 2 years in the 2 non-comparative arms

    2 years proportion of MIBC bladder preserved participants in each tetra-modality arm.

    Time frame: 2 years

Secondary outcomes

  1. Response rate post-induction

    Response rate of participants in each arm following induction chemo/immunotherapy

    Time frame: At week 17 (after 4 months of induction)

  2. Quality of life

    Effect of each tetra-modality arm on the quality of life of participants using the Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) questionnaire; FACT-Bl total score range: 0-156 (higher scores mean worse quality of life)

    Time frame: Every 3 weeks (up to 3 months), then every 4 months (up to 1 year)

  3. Safety

    Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]

    Time frame: During treatment (up to 90 days after end of treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Shamseddine A, Abbas N, Temraz S, Al Darazi M, Charafeddine M, Dagher K, Youssef B, Nasr R, Khauli R, El Hajj A, Bulbul M. Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01). Future Oncol. 2025 Dec;21(30):3873-3884. doi: 10.1080/14796694.2025.2549244. Epub 2025 Aug 25. PubMed 40851456 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2028, 38 months after the start.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's planned 38 months is below that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

Start moved once since we started tracking on Sep 25, 2026: Apr 2025 → Jun 2025, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 13, 2024
StartActual
Jun 11, 2025was Apr 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 15, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • American University of Beirut · Beirut, Lebanon
Show 1 removed
  • American University of Beirut · Beirut, Lebanon
Oct 29, 2026
Start date
Apr 15, 2025→Jun 11, 2025 (actual)
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Efficacy of Avelumab in 2 non-comparative armsNow to assess the proportion of patients who are radical cystectomy free at 2 years in the 2 non-comparative armsTime frame: 2 years
Oct 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40851456 ↗
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40851456 ↗
    1 site added, 1 site removed
    Show site
    • American University of Beirut · Beirut, Lebanon
    Show 1 removed
    • American University of Beirut · Beirut, Lebanon
    Start date Apr 15, 2025→Jun 11, 2025 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Efficacy of Avelumab in 2 non-comparative armsNow to assess the proportion of patients who are radical cystectomy free at 2 years in the 2 non-comparative armsTime frame: 2 years
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06686381
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Jun 11, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Ali I. Shamseddine, MD, FRCP, ESCO
Contact
as04@aub.edu.lb
9311350000 ext. 5390

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion